Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A case report

Diabetes Research and Clinical Practice

Volumn 93, Issue 2, 2011, Pages

  Lee, Yenna ^a   Jung, Hye Seung ^a   Choi, Hyung Jin ^a   Kim, Min Joo ^a   Kim, Tae Min ^a   Park, Kyong Soo ^a   Kim, Seong Yeon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Hypoglycemia; Pancreatic neuroendocrine tumor; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

GLUCOSE; INSULIN; PREDNISONE; SUNITINIB;

ADULT; ARTICLE; BEDTIME DOSAGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; FATALITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PATIENT MONITORING;

ADULT; ANTINEOPLASTIC AGENTS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; HYPOGLYCEMIA; INDOLES; MALE; NEUROENDOCRINE TUMORS; PREDNISOLONE; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 80051560915     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.04.011     Document Type: Article

References (10)

1. Templeton A., Brändle M., Cerny T., Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008, 19:824-825.
2. Billemont B., Medioni J., Taillade L., Helley D., Meric J.B., Rixe O., et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008, 99(9):1380-1382.
3. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25(7):884-896.
4. Chousan J.D., Zamarripa D.E., Lai P.H., Oramasionwu C.U., Grabinski J.L. Sunitinib: a novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract 2007, 13(1):5-15.
5. Louvet C., Szot G.L., Lee M.R., Martinier N., Bollag G., Zhu S., et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008, 105(48):18895-18900.
6. Hägerkvist R., Sandler S., Mokhtari D., Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007, 21(2):618-628.
7. Hägerkvist R., Makeeva N., Elliman S., Welsh N. Imatinib mesylate (Gleevec) protects against streptozocin-induced diabetes and islet cell death in vitro. Cell Biol Int 2006, 30(12):1013-1017.
8. Han M.S., Chung K.W., Cheon H.G., Rhee S.D., Yoon C.H., Lee M.K., et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 2009, 58(2):329-336.
9. Hägerkvist R., Jansson L., Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 2008, 114(1):65-71.
10. Mokhtari D., Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 2009, 118(4):241-247.